EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Genetic drivers of liver cirrhosis: The role of SERPINA1 and PNPLA3 variants in disease onset and progression

Mikolas Holinka iD, Sona Frankova iD, Svetlana Adamcova Selcanova, Lubomir Skladany iD, Ondrej Fabian, Martin Kveton iD, Dusan Merta, Vera Adamkova, Jaroslav A Hubacek, Veronika Pitova, Sarka Vesela, Tomas Hucl und 2 weitere

PLOS One · 2025

DOI: 10.1371/journal.pone.0333051 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Mikolas Holinka und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. Hauptthemen laut MEDLINE: alpha 1-Antitrypsin, Lipase, Liver Cirrhosis, Membrane Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health of the Czech Republic, Ministerstvo Zdravotnictvà Ceské Republiky.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

SERPINA1 Z and PNPLA3 G alleles are the most potent genetic risk modifiers in chronic liver disease (CLD) progression. We aimed to test the impact of concomitant carriage of these variants on the progression of CLDs of various aetiology. The cirrhosis cohort included 1583 individuals with CLD, evaluated as candidates for liver transplantation (LTx), with alcoholic-related liver disease (ALD), metabolic dysfunction-associated (MASLD), viral (VIR), autoimmune/cholestatic (AIH-CHOL), and metabolic conditions (MET). This cohort was compared to a control population of 3483 healthy individuals. The frequency of SERPINA1 MZ heterozygotes was significantly higher (p < 0.0001) in the entire cirrhosis group (84/1583; 5.3%) than in controls (89/3483; 2.6%), OR 2.57 (95% CI 1.92–3.44). The frequency of SERPINA1 MZ heterozygotes was significantly higher in the subgroups with ALD and MASLD (37/557; 6.4% and 23/208; 11.1%, respectively, p < 0.0001); the frequency in the subgroups VIR, AIH-CHOL and MET did not differ from controls. The frequency of the PNPLA3 G allele was significantly higher (p < 0.0001) in the entire cirrhosis group (880/1,583; 55.6%) than in controls (1418/3402; 41.6%); OR 1.48 (95% CI 1.36–1.99). The G allele frequency was significantly higher only in ALD, MASLD and VIR subgroups (392/577, 67.9%; 133/208, 63.9% and 139/264, 52.7%; p < 0.0001, 0.0001 and 0.0005, respectively). The frequency of the PNPLA3 G allele was the same in cirrhotic patients carrying SERPINA1 MM and MZ genotypes (824/1483, 55.6% vs 50/84, 59.2%, N.S.). SERPINA1 MZ heterozygotes with ALD and MASLD were significantly younger (56.9 vs 60 years, p = 0.046) and had a higher MELD score (17 vs 15 points, p = 0.0003) at waitlisting, whereas the PNPLA3 genotype had no impact on the age and MELD score at waitlisting. We conclude that both variant alleles increase the risk of liver cirrhosis in ALD and MASLD; however, SERPINA1 MZ heterozygotes have more progressive chronic liver disease and need LT at a younger age.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

alpha 1-AntitrypsinLipaseLiver CirrhosisMembrane ProteinsHumansMaleFemaleMiddle AgedDisease ProgressionGenetic Predisposition to DiseaseAdultAllelesPolymorphism, Single NucleotideAgedCase-Control StudiesHeterozygoteAcyltransferasesPhospholipases A2, Calcium-Independent

Substanzen

alpha 1-AntitrypsinPNPLA3 protein, humanLipaseSERPINA1 protein, humanMembrane ProteinsAcyltransferasesPhospholipases A2, Calcium-Independent

Autor:innen und Institutionen

  • Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
  • Third Faculty of Medicine, Charles University, Prague, Czech Republic.
  • HEGITO-Department of Hepatology, Gastroenterology and Liver Transplantation of 2nd Department of Internal Medicine, F. D. Roosevelt University Hospital, Banska Bystrica, Slovakia.
  • 2nd Department of Internal Medicine, L. Pasteur University Hospital and P. J. Safarik University, Kosice, Slovakia.
  • Clinical and Transplant Pathology Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
  • Department of Pathology and Molecular Medicine, Third Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic.

ORCID-Profile: Mikolas Holinka, Sona Frankova, Lubomir Skladany, Martin Kveton

Förderung

  • Ministry of Health of the Czech Republic
  • Ministerstvo Zdravotnictvà Ceské Republiky

Zitieren

APA

Holinka, M., Frankova, S., Adamcova Selcanova, S., Skladany, L., Fabian, O., Kveton, M., Merta, D., Adamkova, V., Hubacek, J. A., Pitova, V., Vesela, S., Hucl, T., Jirsa, M., & Sperl, J. (2025). Genetic drivers of liver cirrhosis: The role of SERPINA1 and PNPLA3 variants in disease onset and progression. PLOS One. https://doi.org/10.1371/journal.pone.0333051

Vancouver

Holinka M, Frankova S, Adamcova Selcanova S, Skladany L, Fabian O, Kveton M, et al. Genetic drivers of liver cirrhosis: The role of SERPINA1 and PNPLA3 variants in disease onset and progression. PLOS One. 2025. doi:10.1371/journal.pone.0333051

BibTeX
@article{Holinka2025,
  author = {Holinka, Mikolas and Frankova, Sona and Adamcova Selcanova, Svetlana and Skladany, Lubomir and Fabian, Ondrej and Kveton, Martin and Merta, Dusan and Adamkova, Vera and Hubacek, Jaroslav A and Pitova, Veronika and Vesela, Sarka and Hucl, Tomas and Jirsa, Milan and Sperl, Jan},
  title = {Genetic drivers of liver cirrhosis: The role of SERPINA1 and PNPLA3 variants in disease onset and progression},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0333051}
}
Kostenlos starten →